BMS Mezigdomide Data Bolsters Growth Portfolio, but Wait-for-Margin Discipline Remains

What happened

Bristol Myers Squibb announced that its CELMoD mezigdomide reduced the risk of disease progression or death by over 50% versus standard of care in relapsed/refractory multiple myeloma, bolstering the company's pipeline credibility. This adds to the Growth Portfolio momentum, which grew 17% in FY2025, but the near-term investment thesis remains anchored to Eliquis volume and consolidated gross margin stability as the IRA and Medicaid changes take effect in 2026. The mezigdomide data is a positive catalyst but does not alter the policy-driven margin risks that will be tested in Q1-Q2 2026 prints. Management's 2026 guidance implies revenue of $46.0B–$47.5B and non-GAAP gross margin of ~69–70%, and the drug is still awaiting regulatory submission, so revenue impact is years away. Thus, while the pipeline narrative strengthens, the stock's valuation still hinges on observable execution of the Eliquis bridge year.

Implication

The mezigdomide readout supports the bull case by adding a potential blockbuster to the Growth Portfolio, potentially increasing the probability that pipeline catalysts can offset legacy erosion. However, the stock's re-rating still requires consistent gross margin execution in the first half of 2026, as the IRA and Medicaid policy changes directly impact Eliquis net pricing. Investors should not chase the stock on pipeline news alone; the core risk remains a gross margin break below 69%, which would trigger a de-rating. If Q1-Q2 2026 prints show Eliquis tracking +10-15% growth and gross margin holding 69-70%, the mezigdomide data adds upside optionality toward the $65 base case or higher. Until then, the wait-and-see stance is prudent, with an attractive entry below $55.

Thesis delta

The mezigdomide data incrementally strengthens the bull case by adding a high-potential asset to the pipeline, increasing the likelihood that future catalysts can offset legacy revenue declines. However, it does not change the near-term dependency on Eliquis bridge-year performance and gross margin stability, so the WAIT rating remains intact. The thesis now has a slightly more favorable risk/reward skew if gross margin holds, but the core risk—gross margin breaking below 69%—is unchanged.